Instil Bio Inc（TIL）财务数据TILInstil Bio Inc

Evaluating the bottom line, Instil Bio, Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -25.33%, provide a clear picture of how effectively TIL converts its operational activities into shareholder value.

In the context of the broader market, TIL competes directly with industry leaders such as MREO and IMA. With a market capitalization of $46.31M, it holds a significant position in the sector. When comparing efficiency, TIL's gross margin of N/A stands against MREO's N/A and IMA's N/A. Such benchmarking helps identify whether Instil Bio, Inc. is trading at a premium or discount relative to its financial performance.

Instil Bio has reported continuous net losses, with the latest net loss per share at -$0.63 for Q2 2026, improving from -$3.24 in Q2 2025. The company has also seen a significant reduction in R&D expenses, which may impact future growth.